Aripiprazole, a novel atypical antipsychotic drug.

Author(s): Argo TR, Carnahan RM, Perry PJ

Affiliation(s): College of Pharmacy, University of Iowa, Iowa City, Iowa 52242-1112, USA.

Publication date & source: 2004-02, Pharmacotherapy., 24(2):212-28.

Publication type: Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial

Before the 1990s, treatment of psychoses centered on conventional agents whose tolerability was limited by extrapyramidal side effects (EPS). The past decade has seen the emergence of a newer generation of antipsychotic agents, first with clozapine and followed shortly by risperidone, olanzapine, quetiapine, and ziprasidone. These agents have been touted as providing better negative symptom efficacy, less impaired cognition, and lower risk of extrapyramidal syndromes. However, evolving evidence suggests that several drugs in this class may be associated with significant weight gain and lipid abnormalities. Aripiprazole, a new atypical antipsychotic drug, displayed efficacy similar to that of haloperidol and risperidone and superior to that of placebo in numerous clinical trials. Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Patients receiving aripiprazole experienced EPS at a rate similar to that seen with placebo. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy.